Ocugen Advances Gene Therapy for Blindness with Strategic Deals and Clinical Progress

Ocugen reported Q2 2025 financial results, with a cash position of $27.3 million and a net loss of $0.05 per share. The company secured a Korean licensing deal for OCU400 worth up to $11 million plus royalties and initiated dosing for the OCU410ST Phase 2/3 GARDian3 pivotal trial. Ocugen also announced a strategic reverse merger of its OrthoCellix subsidiary with Carisma Therapeutics.